[1]
|
Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249.
https://doi.org/10.3322/caac.21660
|
[2]
|
De Jong, M.C., Pulitano, C., Ribero, D., et al. (2009) Rates and Patterns of Recurrence Following Curative Intent Surgery for Colorectal Liver Metastasis: An International Multi-Institutional Anal-ysis of 1669 Patients. Annals of Surgery, 250, 440-448. https://doi.org/10.1097/SLA.0b013e3181b4539b
|
[3]
|
Adam, R., Delvart, V., Pascal, G., et al. (2004) Rescue Sur-gery for Unresectable Colorectal Liver Metastases Downstaged by Chemotherapy: A Model to Predict Long-Term Sur-vival. Annals of Surgery, 240, 644-657.
https://doi.org/10.1097/01.sla.0000141198.92114.f6
|
[4]
|
Timmerman, R.D., et al. (2009) Local Surgical, Ablative, and Radiation Treatment of Metastases. CA: A Cancer Journal for Clinicians, 59, 145-170. https://doi.org/10.3322/caac.20013
|
[5]
|
Adam, R., et al. (2009) Patients with Initially Unresectable Colorectal Liver Metastases: Is There a Possibility of Cure? Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 27, 1829-1835.
https://doi.org/10.1200/JCO.2008.19.9273
|
[6]
|
中国医师协会外科医师分会, 中华医学会外科学分会胃肠外科学组, 中华医学会外科学分会结直肠外科学组, 等. 中国结直肠癌肝转移诊断和综合治疗指南(2023) [J]. 中国临床医学, 2023, 30(1): 166-198.
|
[7]
|
Haraldsdottir, S., Wu, C., Bloomston, M., et al. (2013) What Is the Optimal Neo-Adjuvant Treatment for Liver Metastasis? Therapeutic Advances in Medical Oncology, 5, 221-234. https://doi.org/10.1177/1758834013485111
|
[8]
|
张钰洋, 陈善稳, 王鹏远, 等. 结直肠癌肝转移转化治疗的研究进展[J]. 中华胃肠外科杂志, 2021, 24(1): 85-93.
|
[9]
|
National Comprehensive Cancer Network (2023) NCCN Clinical Practice Guidelines in Oncology: Colon Cancer. Version 3, 2022.
|
[10]
|
Van Cutsem, E., et al. (2016) ESMO Consensus Guidelines for the Management of Patients with Metastatic Colorectal Cancer. Annals of Oncology, 27, 1386-1422.
|
[11]
|
Khattak, M.A., et al. (2012) Survival Differences in Patients with Metastatic Colorectal Cancer and with Single Site Metastatic Disease at Initial Presentation: Results from South Australian Clinical Registry for Advanced Colorectal Cancer. Clinical Colorectal Cancer, 11, 247-254. https://doi.org/10.1016/j.clcc.2012.06.004
|
[12]
|
Bismuth, H., et al. (1996) Resection of Nonresectable Liver Metas-tases from Colorectal Cancer after Neoadjuvant Chemotherapy. Annals of Surgery, 224, 509-520. https://doi.org/10.1097/00000658-199610000-00009
|
[13]
|
Cai, G.-X. and Cai, S.-J. (2012) Multi-Modality Treat-ment of Colorectal Liver Metastases. World Journal of Gastroenterology: WJG, 18, 16-24. https://doi.org/10.3748/wjg.v18.i1.16
|
[14]
|
Fakih, M. (2015) Biologic Therapies in Colorectal Cancer: Indications and Contraindications. American Society of Clinical Oncology Educational Book, 35, e197-e206. https://doi.org/10.14694/EdBook_AM.2015.35.e197
|
[15]
|
Alberts, S.R., Horvath, W.L., Sternfeld, W.C., et al. (2005) Oxaliplatin, Fluorouracil, and Leucovorin for Patients with Unresectable Liver-Only Metastases from Colorectal Cancer: A North Central Cancer Treatment Group Phase II Study. Journal of Clinical Oncology, 23, 9243-9249. https://doi.org/10.1200/JCO.2005.07.740
|
[16]
|
Pozzo, C., Basso, M., Cassano, A., et al. (2004) Neoadjuvant Treatment of Unresectable Liver Disease with Irinotecan and 5-Fluorouracil plus Folinic Acid in Colorectal Cancer Pa-tients. Annals of Oncology, 15, 933-939.
https://doi.org/10.1093/annonc/mdh217
|
[17]
|
王枭杰, 池畔, 林惠铭, 卢星榕, 黄颖, 徐宗斌, 黄胜辉, 叶道雄. 转移灶不可切除的转移性结直肠癌原发灶切除术疗效的Meta分析[J]. 中华消化外科杂志, 2016, 15(2): 140-146.
|
[18]
|
中国医师协会外科医师分会多学科综合治疗专业委员会, 中国抗癌协会大肠癌专业委员会, 沈琳, 顾晋, 金晶. 结直肠癌肺转移多学科综合治疗专家共识(2018版) [J]. 肿瘤综合治疗电子杂志, 2018, 4(4): 1-15.
|
[19]
|
Ye, L.C., Liu, T.S., Ren, L., et al. (2013) Randomized Controlled Trial of Cetuximab plus Chemotherapy for Patients with KRAS Wild-Type Unresectable Colorectal Liver-Limited Metastases. Journal of Clinical Oncology, 31, 1931-1938.
https://doi.org/10.1200/JCO.2012.44.8308
|
[20]
|
Folprecht, G., Gruenberger, T., Bechstein, W.O., et al. (2010) Tumour Response and Secondary Resectability of Colorectal Liver Metastases Following Neoadjuvant Chemotherapy with Cetuximab: The CELIM Randomised Phase 2 Trial. The Lancet Oncology, 11, 38-47. https://doi.org/10.1016/S1470-2045(09)70330-4
|
[21]
|
Karoui, M., Penna, C., Amin-Hashem, M., et al. (2006) In-fluence of Preoperative Chemotherapy on the Risk of Major Hepatectomy for Colorectal Liver Metastases. Annals of Surgery, 243, 1-7.
https://doi.org/10.1097/01.sla.0000193603.26265.c3
|
[22]
|
朱德祥, 许剑民. 2017年中国临床肿瘤学会年会结直肠癌研究进展解析[J]. 中华消化外科杂志, 2017, 16(11): 1101-1104.
|
[23]
|
Beppu, T., Emi, Y., Tokunaga, S., et al. (2014) Liver Resectability of Advanced Liver-Limited Colorectal Liver Metastases Following mFOLFOX6 with Bevaci-zumab (KSCC0802 Study). Anticancer Research, 34, 6655-6662.
|
[24]
|
Shen, C., Hu, H., Cai, Y., et al. (2022) mFOL-FOXIRI with or without Bevacizumab for Conversion Therapy of RAS/BRAF/PIK3CA Mutant Unresectable Colorectal Liver Metastases: The FORBES Non-Randomized Phase II Trial. Annals of Translational Medicine, 10, 171. https://doi.org/10.21037/atm-21-6731
|
[25]
|
Gruenberger, T., Bridgewater, J., Chau, I., et al. (2015) Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in Patients with Initially Unresectable Liver Metastases from Colorectal Cancer: The OLIVIA Multinational Randomised Phase II Trial. Annals of Oncology, 26, 702-708. https://doi.org/10.1093/annonc/mdu580
|
[26]
|
De Roock, W., De Vriendt, V., Normanno, N., et al. (2011) KRAS, BRAF, PIK3CA, and PTEN Mutations: Implications for Targeted Therapies in Metastatic Colorectal Cancer. The Lancet Oncology, 12, 594-603.
https://doi.org/10.1016/S1470-2045(10)70209-6
|
[27]
|
Shi, S.J., Wang, L.J., Wang, G.D., et al. (2013) B7-H1 Ex-pression Is Associated with Poor Prognosis in Colorectal Carcinoma and Regulates the Proliferation and Invasion of HCT116 Colorectal Cancer Cells. PLOS ONE, 8, e76012.
https://doi.org/10.1371/journal.pone.0076012
|
[28]
|
Andre, T., Shiu, K.K., Kim, T.W., et al. (2020) Pembrolizumab versus Chemotherapy for Microsatellite Instability-High/Mismatch Repair Deficient Metastatic Colorectal Cancer: The Phase 3 KEYNOTE-177 Study.
|
[29]
|
Winer, A., Ghatalia, P., Bubes, N., et al. (2019) Dual Checkpoint Inhibition with Ipilimumab plus Nivolumab after Progression on Sequential PD-1/PDL-1 Inhibitors Pembrolizumab and Atezolizumab in a Patient with Lynch Syndrome, Metastatic Colon, and Localized Urothelial Cancer. The Oncologist, 24, 1416-1419.
https://doi.org/10.1634/theoncologist.2018-0686
|
[30]
|
Fumet, J.D., Isambert, N., Hervieu, A., et al. (2018) Phase Ib/II Trial Evaluating the Safety, Tolerability and Immunological Activity of Durvalumab (MEDI4736)(anti-PD-L1) plus Tremelimumab (anti-CTLA-4) Combined with FOLFOX in Patients with Metastatic Colorectal Cancer. ESMO Open, 3, e000375.
https://doi.org/10.1136/esmoopen-2018-000375
|
[31]
|
Shady, W., Petre, E.N., Gonen, M., et al. (2016) Percutane-ous Radiofrequency Ablation of Colorectal Cancer Liver Metastases: Factors Affecting Outcomes—A 10-Year Experi-ence at a Single Center. Radiology, 278, 601-611.
https://doi.org/10.1148/radiol.2015142489
|
[32]
|
Berber, E., Tsinberg, M., Tellioglu, G., et al. (2008) Resection versus Laparoscopic Radiofrequency Thermal Ablation of Solitary Colorectal Liver Metastasis. Journal of Gastrointesti-nal Surgery, 12, 1967-1972.
https://doi.org/10.1007/s11605-008-0622-8
|
[33]
|
De Cobelli, F., Calandri, M., Della Corte, A., et al. (2022) Mul-ti-Institutional Analysis of Outcomes for Thermo Sphere Microwave Ablation Treatment of Colorectal Liver Metastases: The SMAC Study. European Radiology, 32, 4147-4159. https://doi.org/10.1007/s00330-021-08497-2
|
[34]
|
Hong, K., Khwaja, A., Liapi, E., et al. (2006) New Intra-Arterial Drug Delivery System for the Treatment of Liver Cancer: Pre-clinical Assessment in a Rabbit Model of Liver Cancer. Clinical Cancer Research, 12, 2563-2567.
https://doi.org/10.1158/1078-0432.CCR-05-2225
|
[35]
|
Lévi, F.A., Boige, V., Hebbar, M., et al. (2016) Conversion to Resection of Liver Metastases from Colorectal Cancer with Hepatic Artery Infusion of Combined Chemotherapy and Systemic Cetuximab in Multicenter Trial OPTILIV. Annals of Oncology, 27, 267-274. https://doi.org/10.1093/annonc/mdv548
|
[36]
|
Martin, R.C.G., Scoggins, C.R., Schreeder, M., et al. (2015) Ran-domized Controlled Trial of Irinotecan Drug-Eluting Beads with Simultaneous FOLFOX and Bevacizumab for Patients with Unresectable Colorectal Liver-Limited Metastasis. Cancer, 121, 3649-3658. https://doi.org/10.1002/cncr.29534
|
[37]
|
Palma, D.A., Olson, R., Harrow, S., et al. (2020) Stereotactic Ablative Ra-diotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial. Journal of Clinical Oncology, 38, 2830. https://doi.org/10.1200/JCO.20.00818
|
[38]
|
Baltatzis, M. and Siriwardena, A.K. (2019) Liver Resection for Colo-rectal Hepatic Metastases after Systemic Chemotherapy and Selective Internal Radiation Therapy with Yttrium-90 Mi-crospheres: A Systematic Review. Digestive Surgery, 36, 273-280. https://doi.org/10.1159/000490111
|
[39]
|
Bertens, K.A., Hawel, J., Lung, K., et al. (2015) ALPPS: Challenging the Concept of Unresectability—A Systematic Review. In-ternational Journal of Surgery, 13, 280-287. https://doi.org/10.1016/j.ijsu.2014.12.008
|